Egypt is stepping up its push to reinforce its pharmaceutical research landscape by deepening pharmaceutical cooperation with Takeda Pharmaceutical Company, aligning with a wider national agenda to strengthen healthcare capabilities and drug development infrastructure.
In this context, the Egyptian Drug Authority (EDA) convened high-level discussions with a senior Takeda delegation to explore ways to expand joint efforts in scientific research while also enhancing Egyptian patients’ access to innovative treatments. The talks brought together Ali El-Ghamrawy, Chairperson of the EDA, and representatives from Takeda led by Khaled Sary. Conversations centred on advancing ongoing partnership initiatives and identifying new collaboration opportunities that support Egypt’s healthcare strategy and the continued evolution of its pharmaceutical system.
Participants also assessed regulatory frameworks and ongoing initiatives designed to improve medicine availability and facilitate broader access to advanced therapies, particularly in priority therapeutic areas. During the meeting, Takeda representatives highlighted recent progress in clinical trial activities and scientific research within Egypt, underlining the importance of sustained coordination with the Authority to further strengthen national research capabilities and contribute to the country’s scientific ecosystem.
The delegation was additionally briefed on the Authority’s forward-looking plans to enhance intellectual property protection for pharmaceutical products. This direction is expected to strengthen the investment environment, align Egypt more closely with international regulatory standards, and encourage further expansion of the pharmaceutical sector. El-Ghamrawy reaffirmed the Authority’s commitment to advancing research initiatives and broadening the clinical trials framework, noting that these efforts are central to positioning Egypt as a regional hub for pharmaceutical research and development. He emphasised the importance of collaboration with global industry leaders to exchange expertise and drive innovation that benefits Egyptian patients.
Officials from Takeda Pharmaceutical Company welcomed the continued pharmaceutical cooperation, commending the Authority’s role in advancing the national pharmaceutical landscape and research environment. They reiterated plans to scale up operations in Egypt, particularly in research, development, and clinical trials, with the aim of accelerating innovation and expanding access to advanced treatments. The engagement forms part of the Egyptian Drug Authority’s broader strategy to strengthen ties with international pharmaceutical companies and foster partnerships that support long-term sector growth.
